Targeting either the inhibitory checkpoint programmed cell death protein-1 (PD-1) or its ligand (PD-L1) with inhibitory monoclonal antibodies has restored antitumor immunity across multiple tumor types [4–8]. Here, CD274 is linked to neoplasm.